Uterine Fibroids Treatment Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), By Treatment (Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Uterine Fibroids Treatment Market is projected to grow from USD 5.15 billion in 2025 to USD 8.42 billion by 2031, achieving an 8.54% CAGR. As it centers on the therapeutic management of benign uterine tumors called leiomyomas. Market growth is primarily driven by the increasing demand for minimally invasive procedures that preserve fertility and reduce recovery times, such as uterine fibroid embolization and laparoscopic myomectomy. Further advancements in robotic surgical systems and the introduction of novel pharmacological therapies are expanding the treatment landscape, offering viable alternatives to traditional open surgeries. However, a significant barrier remains the lack of patient awareness regarding alternative therapies and a historical over-reliance on major surgery, evidenced by a 2024 survey where 53% of women were primarily offered a hysterectomy, limiting access to modern interventions.
Market Driver
Key drivers for market expansion include significant advancements in minimally invasive surgical techniques, which are fundamentally reshaping treatment by offering effective uterine-sparing alternatives to traditional hysterectomies. Patients' increasing preference for procedures like radiofrequency ablation and hysteroscopic morcellation, which minimize recovery time and preserve fertility, is fueling industry consolidation and investment in novel device platforms, as seen with Hologic's $350 million acquisition of Gynesonics. Concurrently, the commercialization of novel GnRH antagonists is broadening the therapeutic landscape for non-surgical management. These oral pharmacotherapies effectively control heavy menstrual bleeding and reduce fibroid volume, addressing a critical gap for women ineligible for or averse to surgery, with treatments like Myfembree showing a 32% year-over-year revenue increase, crucial amidst a rising global incidence rate of uterine fibroids reaching 250.93 per 100,000 women.
Market Challenge
A major impediment to the growth of the Global Uterine Fibroids Treatment Market is the persistent lack of patient awareness regarding alternative therapies, coupled with a historical over-reliance on major surgery. This information asymmetry leads to a continued preference for radical surgical interventions like hysterectomies, thereby removing patients from the addressable market for fertility-preserving devices and long-term management therapies. Consequently, manufacturers of non-surgical solutions face substantial difficulty in market penetration and achieving projected revenue targets. This challenge is underscored by a 2024 survey from the Society of Interventional Radiology, which indicated that 17% of women mistakenly believed a hysterectomy was the only available treatment, directly hindering demand for less invasive options like uterine fibroid embolization and underutilizing the market potential for emerging therapeutic segments.
Market Trends
Notable market trends include advancements in image-guided non-invasive ablation technologies, which are establishing a new therapeutic class distinct from traditional minimally invasive surgery. Technologies such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) use high-intensity sound waves to destroy fibroid tissue through intact skin, offering a completely non-invasive approach that preserves uterine integrity and eliminates surgical recovery time, appealing to patients seeking fertility-sparing options without surgical risks. The rapid clinical acceptance of this incision-less modality is highlighted by uterine fibroids being a leading indication among over one million patients treated with focused ultrasound technologies worldwide in 2025. Additionally, the migration of procedures to outpatient and ambulatory surgical settings is reshaping service delivery, driven by payer incentives for cost reduction and the availability of office-ready devices, leading to increased utilization of systems like MyoSure and Sonata in outpatient gynecological facilities, contributing to robust revenue growth for companies like Hologic.
Key Market Players
* Gynesonics Inc.
* Medtronic Plc.
* Boston Scientific Corporation
* Karl Storz Gmbh
* Pfizer Inc.
* Abbvie Inc.
* Richard Wolf GmbH
* CooperSurgical Inc.
* Olympus Corporation
* Myovant Sciences GmbH
Report Scope
In this report, the Global Uterine Fibroids Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Uterine Fibroids Treatment Market, By Type
* Subserosal Fibroids
* Intramural Fibroids
* Submucosal Fibroids
* Pedunculated Fibroids
# Uterine Fibroids Treatment Market, By Treatment
* Hormone Therapy
* Androgens
* Gonadotropin-Releasing Hormone Antagonists
* Uterine Artery Embolization
* Myomectomy
* Hysterectomy
# Uterine Fibroids Treatment Market, By End-User
* Hospitals & Clinics
* Ambulatory Surgical Centers
* Others
# Uterine Fibroids Treatment Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroids Treatment Market.
Available Customizations:
Global Uterine Fibroids Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Uterine Fibroids Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
5.2.2. By Treatment (Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy)
5.2.3. By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Uterine Fibroids Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Treatment
6.2.3. By End-User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Uterine Fibroids Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Treatment
6.3.1.2.3. By End-User
6.3.2. Canada Uterine Fibroids Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Treatment
6.3.2.2.3. By End-User
6.3.3. Mexico Uterine Fibroids Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Treatment
6.3.3.2.3. By End-User
7. Europe Uterine Fibroids Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Treatment
7.2.3. By End-User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Uterine Fibroids Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By End-User
7.3.2. France Uterine Fibroids Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By End-User
7.3.3. United Kingdom Uterine Fibroids Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By End-User
7.3.4. Italy Uterine Fibroids Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Treatment
7.3.4.2.3. By End-User
7.3.5. Spain Uterine Fibroids Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Treatment
7.3.5.2.3. By End-User
8. Asia Pacific Uterine Fibroids Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatment
8.2.3. By End-User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Uterine Fibroids Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By End-User
8.3.2. India Uterine Fibroids Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By End-User
8.3.3. Japan Uterine Fibroids Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By End-User
8.3.4. South Korea Uterine Fibroids Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Treatment
8.3.4.2.3. By End-User
8.3.5. Australia Uterine Fibroids Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Treatment
8.3.5.2.3. By End-User
9. Middle East & Africa Uterine Fibroids Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatment
9.2.3. By End-User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Uterine Fibroids Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By End-User
9.3.2. UAE Uterine Fibroids Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By End-User
9.3.3. South Africa Uterine Fibroids Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By End-User
10. South America Uterine Fibroids Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Treatment
10.2.3. By End-User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Uterine Fibroids Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Treatment
10.3.1.2.3. By End-User
10.3.2. Colombia Uterine Fibroids Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Treatment
10.3.2.2.3. By End-User
10.3.3. Argentina Uterine Fibroids Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Treatment
10.3.3.2.3. By End-User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Uterine Fibroids Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Gynesonics Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Medtronic Plc.
15.3. Boston Scientific Corporation
15.4. Karl Storz Gmbh
15.5. Pfizer Inc.
15.6. Abbvie Inc.
15.7. Richard Wolf GmbH
15.8. CooperSurgical Inc.
15.9. Olympus Corporation
15.10. Myovant Sciences GmbH
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們